Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis.

ABSTRACT: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1^mut) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1^wt). To assess the clinical outcomes of AML with and without RUNX1^mut, we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1^mut; 108 with RUNX1^wt). There were no significant differences in the median OS and RFS of the RUNX1^mut and RUNX1^wt groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de no

SUBMITTER: Rungjirajittranon T 

PROVIDER: S-EPMC9659296 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature